Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
Jonathan D RavidLuke J LaffinPublished in: Current cardiology reports (2022)
Activation of the MR upregulates genes encoding for facilitators of tissue damage. Finerenone binding to a helix domain in this receptor inhibits receptor function. Studies in murine models of kidney disease, heart failure, hypertension, and vascular injury demonstrate significant protective effects of finerenone against further disease progression, as well as association with reduced oxidative stress, inflammation, and fibrosis. Phase 1-3 clinical trials with finerenone show safety and efficacy in improving renal and cardiovascular outcomes in patients with CKD. Research thus far encourages the addition of finerenone to the standard of care for certain CKD patients, especially those especially at risk for or with pre-existing cardiovascular disease. Continued study of the effect of finerenone in diverse patient populations and different disease states is needed.
Keyphrases
- chronic kidney disease
- end stage renal disease
- oxidative stress
- cardiovascular disease
- blood pressure
- heart failure
- clinical trial
- peritoneal dialysis
- healthcare
- type diabetes
- ejection fraction
- newly diagnosed
- dna damage
- case report
- randomized controlled trial
- heart rate
- hypertensive patients
- prognostic factors
- magnetic resonance imaging
- pain management
- induced apoptosis
- quality improvement
- chronic pain
- cardiovascular events
- diabetic rats
- ischemia reperfusion injury
- gene expression
- dna methylation
- binding protein
- study protocol
- signaling pathway
- contrast enhanced
- heat shock protein
- heat shock